|
Aug 6
|
MetaVia Extends 48 mg MAD Portion of Its Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity to 8 Weeks and Announces Fifth Weekly Dose in First Patient
|
|
Aug 4
|
MetaVia Announces AI-Driven Collaboration with Syntekabio to Explore Additional Indications for DA-1241
|
|
Jun 27
|
OTC Markets Hosts Virtual Investor Presentation with HH Kim, President and CEO of MetaVia Inc., and David Bautz, PhD, Senior Analyst at Zacks SCR
|
|
May 22
|
MTVA: Additional Positive Topline Results for DA-1726 in Phase 1 MAD Study…
|
|
May 20
|
Presenting on Emerging Growth Conference 82 Day 1 on May 21; Register to live stream
|